Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial

Roche (SIX: RO, ROG; OTCQX: RHHBY) will present the initial results from a Phase Ib study evaluating the efficacy and safety for the combination of…

View More Roche’s ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial